Tumor angiogenesis - PubMed (original) (raw)

Review

Tumor angiogenesis

J Folkman. Adv Cancer Res. 1985.

Abstract

The hypothesis that tumors are angiogenesis dependent has, in the past decade, generated new investigations designed to elucidate the mechanism of angiogenesis itself. Many laboratories are now engaged in this pursuit. Some are studying angiogenesis that occurs in physiological situations, whereas others are interested in angiogenesis that dominates pathological conditions. These efforts have led to (1) the development of bioassays for angiogenesis; (2) the partial purification and, in one case, the complete purification of angiogenic factors from neoplastic and non-neoplastic cells; (3) the development of new polymer technology for the sustained release of these factors and other macromolecules in vivo; (4) the cloning and long-term culture of capillary endothelial cells; (5) the demonstration of the role of nonendothelial cells, such as mast cells in modulating angiogenesis; (6) the discovery of angiogenesis inhibitors; and (7) the demonstration that certain animal tumors will regress when angiogenesis is inhibited. The effects of angiogenesis inhibitors provide perhaps the most compelling evidence for the role of angiogenesis in tumor growth. It is conceivable that the original effort to understand the role of angiogenesis in tumor growth will also lead to the use of angiogenesis inhibitors as a new class of pharmacologic agents in a variety of non-neoplastic diseases such as arthritis, psoriasis, and ocular neovascularization. However, much work remains to be done before it will be possible to understand (1) the regulatory systems that govern capillary density in normal tissues; (2) the factors that maintain the viability of microvascular endothelium; (3) the development of the vascular system itself; and (4) the mechanism by which vascular regression occurs, both in the embryo and in the postnatal organism. A knowledge of the mechanisms which underlie these normal processes may help to enlarge our comprehension of tumor angiogenesis.

PubMed Disclaimer

Cited by

Juxtacrine and paracrine interactions of rat marrow-derived mesenchymal stem cells, muscle-derived satellite cells, and neonatal cardiomyocytes with endothelial cells in angiogenesis dynamics.
Rahbarghazi R, Nassiri SM, Khazraiinia P, Kajbafzadeh AM, Ahmadi SH, Mohammadi E, Molazem M, Zamani-Ahmadmahmudi M. Rahbarghazi R, et al. Stem Cells Dev. 2013 Mar 15;22(6):855-65. doi: 10.1089/scd.2012.0377. Epub 2012 Dec 12. Stem Cells Dev. 2013. PMID: 23072248 Free PMC article.
A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.
Boult JK, Terkelsen J, Walker-Samuel S, Bradley DP, Robinson SP. Boult JK, et al. PLoS One. 2013 Apr 26;8(4):e63024. doi: 10.1371/journal.pone.0063024. Print 2013. PLoS One. 2013. PMID: 23638177 Free PMC article.
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.
Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. Good DJ, et al. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6624-8. doi: 10.1073/pnas.87.17.6624. Proc Natl Acad Sci U S A. 1990. PMID: 1697685 Free PMC article.
Progression from hormone dependence to autonomy and angiogenesis in mouse mammary tumours.
Oikawa T, Matsuzawa A, Iwaguchi T. Oikawa T, et al. Br J Cancer. 1986 Jul;54(1):91-6. doi: 10.1038/bjc.1986.156. Br J Cancer. 1986. PMID: 2425838 Free PMC article.
Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer.
Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Rettig WJ, et al. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10832-6. doi: 10.1073/pnas.89.22.10832. Proc Natl Acad Sci U S A. 1992. PMID: 1438285 Free PMC article.

Tumor angiogenesis - PubMed (original) (raw)